Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Gilead's 'universal' hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio
Gilead Sciences Epclusa

US regulators have approved Gilead's Epclusa (sofosbuvir/velpatasvir) to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis.

The combination of Gilead's blockbuster Sovaldi (sofosbuvir) and velpatasvir is the first all-all single tablet treatment for all six major forms of hepatitis C.

Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said: “This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C.”

The FDA approval was based in part on clinical trials showing that 95-99% of patients without cirrhosis or with mild cirrhosis who received Epclusa had no virus detected in the blood 12 weeks after finishing treatment, suggesting their infections had been cured.

The drug had been reviewed under the FDA's priority review programme, which provides for an expedited review of drugs that treat serious conditions and, if approved, would provide significant improvement in safety or effectiveness.

John Milligan, president and CEO of Gilead, said: “[This] approval represents a significant advance for patients with HCV genotypes 2 and 3, who previously required more complex and costly regimens.

“As the first and only pan-genotypic cure for hepatitis C, Epclusa has the potential to eliminate the need for genotype testing, which can be a barrier to treatment in certain resource-constrained settings.”

The combination is also set for European approval in the coming months, following its CHMP recommendation alongside Merck & Co's rival Zepatier (elbasvir/grazoprevir) in May.

Epclusa joins Sovaldi and Harvoni (sofosbuvir/ledipasvir), a product specifically indicated for patients with hepatitis C virus genotype 1 infection, in Gilead's hep C portfolio.

Sovaldi and Harvoni brought in sales of $5.3bn and $13.9bn respectively last year, well ahead of new rivals such as AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) which brought in $1.6bn in the same period.

Article by
Dominic Tyer

29th June 2016

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics